Company intelligence / Profile preview

Genhouse Bio

Ownership: Private
Development stage: Other

Overview

Genhouse Bio has advanced several first-in-class or best-in-class small molecule oncology programs into the clinic. Notably, their SHP2 inhibitor GH21 has been outlicensed ex-China to HUYABIO International and entered coordinated global clinical testing. Their pipeline includes a KRAS inhibitor (GH35) in Phase I studies in China, a KIF18A inhibitor (GH2616) recently entering first-in-human trials for solid tumors, and preclinical work on novel Hippo pathway modulators such as YAP1/TEAD inhibitors. The company emphasizes targeting "undruggable" cancer drivers using innovative chemistry platforms.

Therapeutic areas: Oncology
Modalities: Small moleculesAllosteric inhibitors (e.g., SHP2 inhibitor)KIF18A inhibitorYAP1/TEAD interaction inhibitors
Industry: Biotech

Partnerships

HUYABIO International (out-license of ex-China rights to SHP2 inhibitor GH21/HBI‑2376)

Beyond the preview

Go deeper on Genhouse Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genhouse Bio.